EUVIMEDEUVIMED entdecken
Crossref

2‐Propyl‐3‐Aminoquinazoline‐4(3 H )‐one Derivatives as Potential Androgen Receptor Inhibitors: Synthesis and Cytotoxicity Against PC3 Cell Line via In Vitro and In Silico Studies

Halil Şenol iD, Furkan Çakır iD, Şeyma Ateşoğlu, Pelin Tokalı, Ayşe Merve Şenol, Fahri Akbaş, Feyzi Sinan Tokalı iD

Archiv der Pharmazie · 2025-07 · 358 (7)

DOI: 10.1002/ardp.70048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 10.07.2025. Verfasst von Halil Şenol und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Antineoplastic Agents, Androgen Receptor Antagonists, Receptors, Androgen, Prostatic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: This study was supported by Bezmialem Vakif University under grant number BAP-20230906..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Twenty‐one novel quinazolin‐4(3 H )‐one derivatives were synthesized and evaluated for their cytotoxic effects against the PC3 prostate cancer cell line. Structural characterization was performed using FTIR, NMR, and HRMS spectroscopy. Cytotoxicity assays revealed that compound 1 exhibited the highest potency (IC 50 = 4.29 ± 0.32 µM) and selectivity (SI = 20.1) against PC3 cells, surpassing the reference drug sorafenib. Compounds 10 and 11 also demonstrated significant selectivity (SI = 12.7 and 12.4, respectively), making them promising candidates for further investigation. Molecular docking studies confirmed strong binding affinities to the androgen receptor (AR), with compound 1 displaying the most favorable interaction (IFD Glide Score = −15.137 kcal/mol, MM‐GBSA = –72.11 kcal/mol). MD simulations further supported the stability of compound 1 within the receptor binding site, highlighting key hydrogen bonding and π–π stacking interactions. ADME predictions indicated favorable pharmacokinetic properties, with all active compounds complying with drug‐likeness criteria and exhibiting high oral absorption. Overall, these findings suggest that quinazolinone derivatives, particularly compound 1 , hold significant potential as selective anticancer agents targeting prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsAndrogen Receptor AntagonistsReceptors, AndrogenProstatic NeoplasmsQuinazolinonesQuinazolinesHumansMolecular Docking SimulationStructure-Activity RelationshipMolecular StructureDrug Screening Assays, AntitumorMalePC-3 CellsDose-Response Relationship, DrugCell SurvivalCell Proliferation

Stichwörter der Autor:innen

ADMEandrogen receptormolecular dockingprostate cancerquinazolin‐4(3H)‐one

Substanzen

Antineoplastic AgentsAndrogen Receptor AntagonistsReceptors, AndrogenQuinazolinonesQuinazolinesAR protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, Istanbul, Türkiye.
  • Institute of Health Sciences, Department of Biotechnology, Bezmialem Vakif University, Fatih, Istanbul, Türkiye.
  • Faculty of Medicine, Department of Medical Biology, Bezmialem Vakif University, Fatih, Istanbul, Türkiye.
  • Department of Veterinary Physiology, Faculty of Veterinary Medicine, Kafkas University, Kars, Türkiye.
  • Program of Medical Laboratory Techniques, Department of Medical Services and Techniques, University of Health Sciences, Üsküdar, Istanbul, Türkiye.
  • Kars Vocational School, Department of Material and Material Processing Technologies, Kafkas University, Kars, Türkiye.

ORCID-Profile: Halil Şenol, Furkan Çakır, Feyzi Sinan Tokalı

Förderung

  • This study was supported by Bezmialem Vakif University under grant number BAP-20230906.

Zitieren

APA

Şenol, H., Çakır, F., Ateşoğlu, Ş., Tokalı, P., Şenol, A. M., Akbaş, F., & Tokalı, F. S. (2025). 2‐Propyl‐3‐Aminoquinazoline‐4(3 H )‐one Derivatives as Potential Androgen Receptor Inhibitors: Synthesis and Cytotoxicity Against PC3 Cell Line via In Vitro and In Silico Studies. Archiv der Pharmazie, 358(7). https://doi.org/10.1002/ardp.70048

Vancouver

Şenol H, Çakır F, Ateşoğlu Ş, Tokalı P, Şenol AM, Akbaş F, et al. 2‐Propyl‐3‐Aminoquinazoline‐4(3 H )‐one Derivatives as Potential Androgen Receptor Inhibitors: Synthesis and Cytotoxicity Against PC3 Cell Line via In Vitro and In Silico Studies. Archiv der Pharmazie. 2025;358(7). doi:10.1002/ardp.70048

BibTeX
@article{enol2025,
  author = {Şenol, Halil and Çakır, Furkan and Ateşoğlu, Şeyma and Tokalı, Pelin and Şenol, Ayşe Merve and Akbaş, Fahri and Tokalı, Feyzi Sinan},
  title = {2‐Propyl‐3‐Aminoquinazoline‐4(3 H )‐one Derivatives as Potential Androgen Receptor Inhibitors: Synthesis and Cytotoxicity Against PC3 Cell Line via In Vitro and In Silico Studies},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {7},
  doi = {10.1002/ardp.70048}
}
Kostenlos starten →